news
Peginterferon-lambda accelerates COVID-19 recovery, finds trial
Peginterferon-lambda rapidly reduced non-hospitalised COVID-19 patients’ viral loads and expedited their recovery in a Phase II study.
List view / Grid view
Johns Hopkins University
article
How will Trump’s ‘Buy American’ executive order impact pharmaceutical supply chains?
On 6 August 2020, US President Donald Trump signed an executive order, dubbed ‘Buy American’, with the aim of increasing the production of essential medicines in the US for domestic use. Here, Victoria Rees discusses the order and what it means for drug manufacturers in the US and rest of…
article
Bioprocessing & Bioproduction In-Depth Focus 2019
This In-Depth Focus includes articles estimating the long-term stability of mAbs and exploring an automated approach in continuous biopharma production.
news
Collaboration to produce new clinical stage TB drug candidates
The National Institute of Allergy and Infectious Diseases (NIAID) has awarded TB Alliance a CETR grant for tuberculosis drug development.
news
PET tracer able to image tau in Alzheimer’s disease patients
Research into detecting tau proteins in the brains of Alzheimer's patients has shown that a specific tracer could detect and measure the protein levels...
news
Boosting the safety of bulk drug substances is aim of FDA measures
Boosting the safety of compounded drugs is the aim of new plan from the US Food and Drug Administration (FDA), which has unveiled a series of measures.
news
ITI-214 Parkinson’s drug may be useful for heart failure patients
A drug currently in trials for Parkinson's disease has shown promise in treating heart failure, without the risk of dangerous side effects...
news
Direct anticoagulants associated with increased risk of bleeding
Results of a study suggest the need for caution in the prescription of direct oral anticoagulants for patients with chronic kidney disease, due to the risk of bleeding...
news
Treatment for MRSA no longer more costly than for susceptible Staph aureus infections
A new study found that infections caused by the drug resistant bacteria - methicillin-resistant Staphylococcus aureus, known as MRSA - are no more expensive to treat than MSSA, the methicillin-susceptible version of the same bacteria.
news
Crizotinib-radiation therapy combination may help preserve hearing in NF2
Adding the targeted cancer therapy drug crizotinib to radiation therapy for tumours associated with the genetic disorder neurofibromatosis 2 may reduce the hearing damage that can be exacerbated by radiotherapy...
news
Topical valsartan found to be effective in accelerating chronic wound healing
A topical gel made from a class of common blood pressure medications has been found to accelerate the healing process of chronic skin wounds...
news
Experimental nano-chemo particle to treat bladder cancer
Researchers have developed a way to successfully deliver nano-sized, platinum-based chemotherapy drugs to treat a form of bladder cancer...
news
Cancer immunotherapy drugs linked to autoimmune diseases
24 June 2016 | By Victoria White, Digital Content Producer
Some cancer patients taking the immunotherapy drugs ipilimumab and nivolumab may be at a higher-than-normal risk of developing autoimmune diseases...
article
ITC: affinity is not everything
7 February 2009 | By
During the optimisation of drug candidates, improvements in affinity and selectivity play a critical role. This task is usually accomplished by establishing accurate correlations between the affinity/selectivity of different chemical scaffolds and through chemical modifications to a selected scaffold.
article
A new era for microcalorimetry in drug development
21 September 2007 | By Dr Ernesto Freire, Faculty Professor, Johns Hopkins University, Baltimore
Drug development involves the identification and subsequent optimisation of low molecular weight compounds with a desired biological activity. Often, the initial binding affinity of those compounds towards their intended target needs to be improved by five or more orders of magnitude before they become viable drug candidates; a process that…
